Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J
Pharmaceutical Products Division, Abbott Laboratories, North Chicago, Illinois 60045, USA.
Pharm Res. 2001 Jun;18(6):859-66. doi: 10.1023/a:1011052932607.
In the summer of 1998, Norvir semi-solid capsules supplies were threatened as a result of a new much less soluble crystal form of ritonavir. This report provides characterization of the two polymorphs and the structures and hydrogen bonding network for each form.
Ritonavir polymorphism was investigated using solid state spectroscopy and microscopy techniques including solid state NMR, Near Infrared Spectroscopy, powder X-ray Diffraction and Single crystal X-ray. A sensitive seed detection test was developed.
Ritonavir polymorphs were thoroughly characterized and the structures determined. An unusual conformation was found for form II that results in a strong hydrogen bonding network A possible mechanism for heterogeneous nucleation of form II was investigated.
Ritonavir was found to exhibit conformational polymorphism with two unique crystal lattices having significantly different solubility properties. Although the polymorph (form II) corresponding to the "cis" conformation is a more stable packing arrangement, nucleation, even in the presence of form II seeds, is energetically unfavored except in highly supersaturated solutions. The coincidence of a highly supersaturated solution and a probable heterogeneous nucleation by a degradation product resulted in the sudden appearance of the more stable form II polymorph.
1998年夏,由于ritonavir一种新的、溶解度低得多的晶型出现,诺维拉(Norvir)半固体胶囊的供应受到威胁。本报告对这两种多晶型物进行了表征,并给出了每种晶型的结构和氢键网络。
采用固态光谱和显微镜技术研究ritonavir的多晶型现象,这些技术包括固态核磁共振、近红外光谱、粉末X射线衍射和单晶X射线衍射。开发了一种灵敏的晶种检测试验。
对ritonavir的多晶型物进行了全面表征并确定了其结构。发现晶型II具有一种不寻常的构象,这导致了一个强大的氢键网络。研究了晶型II异质成核的一种可能机制。
发现ritonavir表现出构象多晶型现象,具有两种独特的晶格,其溶解特性显著不同。尽管对应于“顺式”构象的多晶型物(晶型II)是一种更稳定的堆积排列,但即使存在晶型II晶种,成核作用在能量上也是不利的,除非在高度过饱和溶液中。高度过饱和溶液与降解产物可能的异质成核作用同时出现,导致更稳定的晶型II多晶型物突然出现。